Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Investor Presentation (November 2025)
32 slides from Cellectis's investor presentation, November 2025
Slide 1: Corporate Presentation November 2025
Corporate Presentation November 2025 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking” statements within the These forward-looking statements are made in light of information meaning of applicable securities laws, including the Private Securities currently available to us and are subject to numerous risks and Liti
Slide 3: Cellectis' Leadership Position in Cell & Gene Therapy
Cellectis’ Leadership Position in Cell & Gene Therapy INNOVATIVE BEST-IN-CLASS END-TO-END STRONG ALLOGENEIC CAR-T GENE EDITING IN-HOUSE PARTNERSHIPS PLATFORM MANUFACTURING 5 ongoing clinical Diversified Financial programs* Backed by Strong IP Upsides 300+ patients treated** (*) 2 Cellectis fully-own
Slide 4: Cellectis Partners with Industry Leaders; Cash Position $225M
Cellectis Partners with Industry Leaders Partnerships with industry leaders: $6bn potential milestones + royalties Cash Position Clinical Trials* $225M* as of September 30, 2025 Expected runway into H2 2027 ** *Cash, cash equivalents and fixed-term deposits include restricted cash of $4.4 million as
Slide 5: TALEN is Best-in-class Gene Editing
TALEN® is Best-in-class Gene Editing NUCLEASE SAFE Low genotoxicity and off-target* Gene replacement, correction, insertion PRECISE Targets precisely any DNA BASE EDITORS Gene editing without CRISPR- associated genotoxicity EFFICIENT High editing efficiencies (up to 100%) GENE MODULATORS VERSATILE V
Slide 6: UCART Design
UCART Design CD52 KO TCRaβ KO CAR CD52 KO TCRaβ KO Resistance to Minimizes risk CAR-T cell anti-CD52 abs of GvHD Abs: Antibodies ; CART: Chimeric Antigen Receptor T-cell ; GvHD: Graft-versus-Host-Disease ; KO: Knock-Out ; UCART: Universal Chimeric Antigen Receptor T-cell 6
Slide 7: Allogeneic CAR-T: Unlocking a Scalable Industrial Approach
Allogeneic CAR-T: Unlocking a Scalable Industrial Approach Healthy donor Cell Cell Frozen UCART Patients cell collection modification amplification product Scalable Manufacturing Off-The-Shelf 1 batch = 100s doses Immediate access and Scalable to 1000s doses attractive gross margins 7
Slide 8: Fully Integrated Manufacturing
Fully Integrated Manufacturing Paris, France Raleigh, NC 14,000 sq ft. facility 82,000 sq ft. facility CMC Development, Starting Materials UCART – Clinical & Intended Ready Site ✓ Process & analytical development ✓ UCART GMP manufacturing Allogeneic CAR-T ✓ Starting materials manufacturing: ✓ QC tes
Slide 9: Advancing an Industry-Leading Pipeline
Advancing an Industry-Leading Pipeline UPCOMING EXPECTED STUDY INDICATION PRECLINICAL PHASE 1 PHASE 21 MILESTONE BALLI-01 Pivotal Phase 2 first interim analysis B-ALL expected in Q4 2026 Lasme-cel (CD22) Fully Owned NATHALI-01 NHL Full Phase 1 dataset expected in Eti-cel (CD20, CD22) 2026 ALPHA 3 LB
Slide 10: Lasme-cel and Eti-cel Differentiated Positioning
Lasme-cel and Eti-cel Differentiated Positioning LCAR-AIO CD19/CD20/CD22 Post-CD19 CAR-T KITE-363/ KITE-753 autologous CD19/CD20 treatments ▪ CD20 & CD22: Differentiated targets validated in oncology C-CARO39 CD19/CD20 ▪ Lasme-cel: Best-in-class allogeneic CD22 CAR-T for B-ALL. ▪ Eti-cel: Unique all
Slide 11: Lasme-cel for patients with relapsed or refractory B-ALL
Lasme-cel for patients with relapsed or refractory B-ALL Lasme-cel is not FDA approved 11
Slide 12: B-ALL: an Unmet Medical Need
B-ALL: an Unmet Medical Need B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA • 1L treated population: ~9,200 Patients (US, EU4, UK)* High relapse in adults CHALLENGES WITH EXISTING TREATMENTS • Chemotherapies: Lead to high relapse rate in adults • ADCs have a limited effect: Low antigen expression • CD19-direct
Slide 13: Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL?
P13 Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL? Allogeneic CAR-T Starts with Healthy-donor T Cells Healthier and less exhausted than autologous cells from heavily pretreated patients Off-the-Shelf is designed for “Speed” – in B-ALL Every Day Counts Standardized, Repeatable Quality All p
Slide 14: Poor Response Rates after Targeted Therapy Failure
Poor Response Rates after Targeted Therapy Failure 1 After targeted therapy failure, salvage chemo yields low ORR and MRD: High unmet need in heavily Post Blina failure Post Ino failure Post CAR-T failure pretreated patients ORR <20% ORR <10-15% ORR <10% MRD-ve <10% MRD-ve <5-10% MRD-ve <5% 1. Inter
Slide 15: BALLI-01 Demographic and Baseline Characteristics
BALLI 01 | Demographic and Baseline Characteristics DL3 P2 All Subjects (n=12) Age ≤ 50 (n=9) Total (n=40) Age (yrs), median (range) 27 (16 - 66) 23 (16 - 45) 27 (16 - 68) Sex, n (%) Male 5 (41.7) 3 (33.3) 22 (55) Female 7 (58.3) 6 (66.7) 18 (45) ECOG PS, n (%) 0 5 (41.7) 4 (44.4) 14 (35) 1 6 (50) 4
Slide 16: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort Overall Response Rate (%) 100% 100 90 83% Cellectis manufactured 80 44% product (P2) is superior 68% 70 to CDMO product (P1) 60 41% 50 32% 40 28% Recommended Phase 30 56% 6% 2 Dose: DL3 20 36% 42% 10 22% 0 Target Phase 2 P1(n=18) P1 (n=18 P2 (n=22) P2 DL3 (n=12) Targ
Slide 17: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort CR/CRi rate with MRD status (%) 60 56% 50 11% 42% 40 36% In Target Phase 2 8% 9% population, 30 22% 80% who achieved 20 45% CR/CRi were also 11% 34% 27% MRD negative 10 11% 0 P1 (n=18 (n=18) P2 (n=22) P2 DL3 (n=12) Target Pivotal Phase 2 Population (n=9) MRD-ve CR/CR
Slide 18: Achieving Transplant: an Important Clinical Outcome
Achieving Transplant: an Important Clinical Outcome Subjects Who Received or Eligible for HSCT (%) 100 90 20% 80 100% 70 Received or 60 Eligible for 50 HSCT 40 80% 75% 30 55% 50% In Phase 2 target 20 population 10 17% 0 P2 Overall P2 DL2 (n=6) P2 DL2i (n=4) P2 DL3 (n=12) Target Pivotal (n=22) Phase
Slide 19: Improved Survival in Patients Who Responded
Improved Survival in Patients Who Responded Overall Survival over 12 months by Response (P2) Median Overall Survival in Subjects who Achieve MRD- negative CR/CRi 16 14.8 14.8 14 12 10 9.4 Months 8 6 4 2 0 P2 DL3 Target Pivotal Phase 2 Population P2 14.8 months DL3 Median overall survival in subjects
Slide 20: High CR/CRi Rates in Patients Exposed to Prior Targeted Therapies
High CR/CRi Rates in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T CR/CRi Rate (in %) in Patients with Prior Exposure to 3 Targeted Therapies: Blin, Ino and CD19 CAR-T 80 70 Deep 60 responses if 50 received all 3 available 40 75% targeted 30 60% therapies 20
Slide 21: Low Incidence of Grade ≥3 CRS and ICANS
Low Incidence of Grade ≥ 3 CRS and ICANS CRS and ICANS: Total Population (n=40) CRS and ICANS: DL3 (n=18) 100 100 90 90 80 5.5 80 70 2.5 Percentage (%) 70 60 39 60 32.5 50 50 40 40 12 30 30 12 20 39 20 37.5 5 10 10 10 17 7.5 0 0 CRS ICANS CRS ICANS Grade1 Grade 2 Grade 3 Grade1 Grade 2 Grade 3 ICANS
Slide 22: No Current Signal for IEC-HS
No Current Signal for IEC-HS Significant interest in the risk of IEC-HS based on prior CD22 targeting autologous CAR-T ▪One case observed in BALLI-01 No evidence of IEC-HS ▪Grade 2 HLH Day 5 CD22 target incidence ▪Resolved with related effect Anakinra/Dex IEC-HS: Immune Effector Cell–Associated Hemo
Slide 23: Study Design: Pivotal Phase 2
Study Design: Pivotal Phase 2 Interim Analysis 1: Interim Analysis 2: Primary Analysis Overall Dose Optimization 50% pivotal Cohort for BLA Survival Primary Endpoint: CR / CRi, evaluated within 3 months (from Day 28 to Day 84) Age 12-50 years Recruitment of patients driven by 75 planned study center
Slide 24: Multiple Catalysts to 2H 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 BLA: Biologics Licence Application 24
Slide 25: Lasme-cel Has the Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 26: Lasme-cel Could Achieve Up To ~$700M in Peak Gross Sales
Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales (U.S., EU4, UK) Assumption Source / Rationale Addressable Patients (#) ~1.1 K ~840 Represents expected 3L CAR-T eligible patients in 2035 x x • Triangulated using physician-reported preferences and average market share of Preference Share (%)
Slide 27: Eti-cel for patients with relapsed or refractory NHL
Eti-cel for patients with relapsed or refractory NHL Eti-cel is not FDA approved 27
Slide 28: Eti-cel: Study Design
Eti-cel: Study Design Dose Escalation Key inclusion criteria: Dose Expansion ▪ Age 18–80 years BOIN design • 2-4 pts/cohort ▪ Mature B-cell NHL except CLL/SLL, Richter’s from CLL/SLL, Burkitt’s lymphoma, or Waldenstrom’s macroglobulinemia 450 × 10 6 cells DL 3 ▪ Tumor positive for CD20 and/or CD22 ▪
Slide 29: Eti-cel: High Response Rates in R/R NHL
Eti-cel: High Response Rates in R/R NHL Response rate (%) [n=7] 100 90 80 70 4/7 CR at 60 Current 50 86% 40 Dose Level 30 57% 20 10 0 ORR CR Update on Program at ASH 2025 29 ASH: American Society of Hematology annual congress
Slide 30: Expected 2026 Catalysts
Expected 2026 Catalysts Lasme-cel Phase 2 first Interim Analysis Eti-cel Potential EoP1 in r/r NHL Preclinical PoC for In Vivo Gene Therapy EoP1: End-of-Phase 1 ; PoC: Proof-of-Concept 30
Slide 31: Thank You
Thank You Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA 31 Cellectis®, TALEN® and our corporate logos are registered
Slide 32: Diversified Partnerships with Industry Leaders
Diversified Partnerships with Industry Leaders CAR-T CAR-T BCMA, CD70 TILs Cell and Gene Therapies CD19 (ALLO-501, Cema-cel) + 13 targets Exclusive worldwide U.S. rights exclusively Exclusive worldwide Research Joint Research and license to CD19- sublicensed to license to 15 collaboration and Collab